View Clinical Trial (Medical Research Study)
A Study of the Safety and Tolerability of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis - NCT00550238-33701(Clinical Trial 188922)
ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.
| City: |
|
St. Petersburg |
|
State:
|
|
FL |
| Zip Code: |
|
33701 |
| Conditions: |
|
Parkinson's Disease Psychosis |
| Purpose: |
|
To assess the long-term safety and tolerability of ACP-103 in subjects with Parkinson's
disease psychosis.
|
| Study summary: |
|
|
| Criteria: |
|
Inclusion Criteria:
- Subject has completed the treatment period of a previous blinded study of
pimavanserin
- The subject is willing and able to provide consent
- Caregiver is willing and able to accompany the subject to all visits
Exclusion Criteria:
- Subject has current evidence of a serious and or unstable cardiovascular,
respiratory, gastrointestinal, renal, hematologic or other medical disorder
- Subject is judged by the Investigator to be inappropriate for the study |
|
|
|
| Study is available at: |
|
St. Petersburg, FL 33701
United States
Primary Contact:
Mary Hoskinson
Email: mhoskinson@acadia-pharm.com
Phone: 858-320-8620 |
|
|
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
|
| Trials Alerts: |
|
If you would like to be
notified of new clinical trials as they become available please
register for a free account.
|
|
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
March 22, 2011 |
Modifications to
this listing: |
|
Only selected fields are shown, please use the link
above to view all information about this clinical trial. |
|
|
|
|
|
|
|
|